USPTO Examiner ALDERSON ANNE MARIE K - Art Unit 3682

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18892119SYSTEMS AND METHODS FOR ENHANCED EXTENDED CARE MANAGEMENT WITH SOCIAL DETERMINANTS OF HEALTHSeptember 2024January 2026Abandon1620YesNo
18770292MEDICAL ASSISTANTJuly 2024September 2024Allow200YesNo
18761890PREDICTING NEWLY INCIDENT CHRONIC KIDNEY DISEASEJuly 2024August 2025Allow1310YesNo
18671396SYSTEM AND METHOD FOR INDIVIDUALIZED HEALTHCARE RECOMMENDATIONSMay 2024August 2025Abandon1410NoNo
18653395AI-ASSISTED TREATMENT OPTIMIZATION LEVERAGING TREATMENT FIDELITY DATAMay 2024March 2025Allow1110YesNo
18437140Artificial intelligence-based cognitive-coping therapy (CCT) method, system, and applicationFebruary 2024January 2026Abandon2310NoNo
18404807COMPUTER VISION MICRO-SERVICE SEIZURE PREVENTION SYSTEMJanuary 2024December 2025Allow2310YesNo
18503126SYSTEMS, DEVICES, AND METHODS FOR DIAGNOSTIC AID KIT APPARATUSNovember 2023April 2025Abandon1810YesNo
18491618AUTOMATED ELECTRONIC MEDICAL RECORD (EMR) ANALYSIS VIA POINT OF CARE COMPUTING SYSTEMSOctober 2023August 2025Allow2210YesNo
18556301SYSTEM, METHOD, AND APPARATUS FOR PET CONDITION DETECTIONOctober 2023January 2026Allow2730YesNo
18489252APPARATUS AND METHODS FOR TRACKING PHARMACEUTICAL SAMPLESOctober 2023March 2026Abandon2910NoNo
18459794CHAOTIC STORAGE OF PRESCRIPTION MEDICATIONSSeptember 2023March 2025Abandon1910NoNo
18239082SYSTEMS AND METHODS FOR DISPENSING MEDICATIONS BASED ON PROXIMITY TO AN ELECTRONIC MEDICATION STORAGE CABINETAugust 2023October 2025Allow2510YesNo
18335160Multi-agent automatic voting system for fast, on-the-fly imaging and diagnosis of retina diseases using case based expert systemsJune 2023February 2026Abandon3210NoNo
18332634Systems and Methods for Facilitating and Evaluating Psychological Shifts in UsersJune 2023March 2026Abandon3320NoNo
18196403HEALTH INFORMATION EXCHANGE SYSTEMMay 2023September 2025Abandon2810NoNo
18300960System, Method, and Computer Program Product for Validating PrescriptionsApril 2023October 2025Abandon3020YesNo
18170582SYSTEMS AND METHODS FOR PROVIDING ELECTRONIC AND NON-ELECTRONIC RECORDSFebruary 2023July 2025Abandon2910NoNo
18007111ANTIMICROBIAL CHOICE ALGORITHM FOR URINARY TRACT INFECTIONSJanuary 2023November 2025Abandon3420NoNo
18101035EQUIPMENT UTILIZATION AND HEALTHCARE TECHNOLOGY MANAGEMENT PLATFORMJanuary 2023May 2025Abandon2810YesNo
18156509METHOD AND APPARATUS FOR PROVIDING CLOUD-BASED MEDICAL COLLABORATION SERVICE FOR MEDICAL IMAGESJanuary 2023November 2025Abandon3410NoNo
18066417SYSTEM FOR TRIGGERING PATIENT ANALYTIC SERVICES FOR A MEDICAL PROVIDERDecember 2022October 2025Allow3410YesNo
18073407MANAGEMENT OF PSYCHIATRIC OR MENTAL CONDITIONS USING DIGITAL OR AUGMENTED REALITY WITH PERSONALIZED EXPOSURE PROGRESSIONDecember 2022July 2024Allow1930YesNo
17933844ELECTRONIC SYSTEM FOR WOUND IMAGE ANALYSIS AND COMMUNICATIONSeptember 2022April 2025Abandon3110NoNo
17908340SYSTEMS AND METHODS FOR INCREASING A SLEEPINESS OF INDIVIDUALSAugust 2022February 2026Allow4241YesNo
17822142INTELLIGENT MEDICAL RESOURCE SHARING PLATFORMAugust 2022June 2025Abandon3420NoNo
17874707Handsfree Communication System and MethodJuly 2022January 2026Allow4230NoNo
17732332DIRECT DATA CONNECTION FOR UNIVERSAL COLLECTION OF HEALTH DATAApril 2022August 2025Abandon3920YesNo
17708790Cognitive behavioral therapy (CBT) method, system and application for managing tinnitusMarch 2022June 2025Abandon3820YesNo
17697593Automated Clinical Documentation System and MethodMarch 2022February 2025Abandon3520NoNo
17592847PATIENT-CENTERED MUSCULOSKELETAL (MSK) CARE SYSTEM AND ASSOCIATED PROGRAMS FOR THERAPIES FOR DIFFERENT ANATOMICAL REGIONSFebruary 2022September 2025Allow4431YesNo
17597916Consultation Assistant For Aesthetic Medical ProceduresJanuary 2022November 2024Abandon3410NoNo
17581339SYSTEM AND METHOD TO PREDICT REPRODUCIBILITY OF CLINICAL BENEFITS OF A NEW DRUGJanuary 2022December 2024Abandon3510NoNo
17580566HEADSET INTEGRATED INTO HEALTHCARE PLATFORMJanuary 2022June 2025Allow4160YesNo
17646387MEDICAL INFORMATION PROCESSING APPARATUSDecember 2021October 2025Abandon4540NoNo
17615860SYSTEMS AND METHODS FOR HOSPITAL ASSET LOGISTICS OPTIMIZATIONDecember 2021July 2025Abandon4330NoNo
17514165METHOD AND SYSTEM TO DETERMINE, TRACK, AND MITIGATE SPECIFIC PHOBIA STIMULATION FOR A PATIENT WITHIN HEALTHCARE SETUPOctober 2021November 2025Abandon4840YesNo
17441496SYSTEM, METHOD AND SOFTWARE PROGRAM FOR MANAGING THE INTERACTION BETWEEN DRUGSSeptember 2021May 2025Abandon4420YesNo
17441037METHOD OF PREDICTING WHETHER A KIDNEY TRANSPLANT RECIPIENT IS AT RISK OF HAVING ALLOGRAFT LOSSSeptember 2021March 2025Abandon4230YesNo
17436840ADAPTIVE CLINICAL TRIALSSeptember 2021April 2025Abandon4330YesNo
17357124ELECTROCARDIOGRAM ANALYSIS MATCHING SUPPORT SERVICE SYSTEMJune 2021September 2025Abandon5140YesNo
17356796CONTACT TRACING UTILIZING DEVICE SIGNATURES CAPTURED DURING TRANSACTIONSJune 2021January 2025Allow4340YesNo
17417070METHOD FOR OPTIMIZATION OF CANNABIS DOSAGE AND MIXTURE OF ACTIVE CANNABINOIDSJune 2021October 2024Abandon3911NoNo
17299433HEALTH MANAGEMENT SYSTEMJune 2021July 2025Abandon4930NoNo
17308829SYSTEM AND METHOD FOR INDIVIDUALIZED HEALTHCARE RECOMMENDATIONSMay 2021November 2024Abandon4220YesNo
17215545SLEEP APNEA TEST DEVICEMarch 2021April 2025Allow4931YesNo
17169392SYSTEMS AND METHODS FOR DETECTING AND TRACKING INFECTIOUS DISEASES USING SENSOR DATAFebruary 2021August 2024Allow4231YesNo
17147593SYSTEM AND METHOD FOR PROCESSING MEDICAL CLAIMS USING BIOMETRIC SIGNATURESJanuary 2021November 2025Allow5830YesNo
17128251DE-ESCALATING SITUATIONSDecember 2020January 2025Abandon4960YesNo
17105825Enhanced Enterprise Image Reading with Search and Direct StreamingNovember 2020February 2025Allow5040YesNo
17045484INFORMATION PROCESSING DEVICE AND INFORMATION PROCESSING METHODOctober 2020March 2025Abandon5360NoNo
16961399METHODS FOR IMPROVING PSYCHOLOGICAL THERAPY OUTCOMEJuly 2020November 2024Abandon5251YesNo
16896889PROVIDER-CURATED APPLICATIONS FOR ACCESSING PATIENT DATA IN AN EHR SYSTEMJune 2020May 2025Abandon5940YesNo
16819133INTELLIGENT HEALTH PROVIDER MONITORING WITH DE-IDENTIFICATIONMarch 2020September 2022Abandon3040NoNo
16340543DEVICE, SYSTEM, AND METHOD FOR OPTIMIZING USAGE OF PRIOR STUDIESApril 2019December 2025Abandon6080NoYes
15867810AUTOMATED FAMILY ALERT SYSTEMJanuary 2018April 2021Abandon3960YesYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ALDERSON, ANNE-MARIE K.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
2
Examiner Affirmed
2
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
17.6%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
3
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
3
(100.0%)
Filing Benefit Percentile
9.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner ALDERSON, ANNE-MARIE K - Prosecution Strategy Guide

Executive Summary

Examiner ALDERSON, ANNE-MARIE K works in Art Unit 3682 and has examined 22 patent applications in our dataset. With an allowance rate of 22.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 48 months.

Allowance Patterns

Examiner ALDERSON, ANNE-MARIE K's allowance rate of 22.7% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ALDERSON, ANNE-MARIE K receive 3.86 office actions before reaching final disposition. This places the examiner in the 97% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ALDERSON, ANNE-MARIE K is 48 months. This places the examiner in the 8% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +33.3% benefit to allowance rate for applications examined by ALDERSON, ANNE-MARIE K. This interview benefit is in the 81% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 9.3% of applications are subsequently allowed. This success rate is in the 4% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 3% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 0.0% of appeals filed. This is in the 2% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 120.0% are granted (fully or in part). This grant rate is in the 95% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 40% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 43% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.